title: The many faces of marginal zone lymphoma.
abstract: Indolent B-cell lymphomas that are supposed to derive from the marginal zone (marginal zone lymphomas [MZLs]) include 3 specific entities: extranodal marginal zone lymphoma (EMZL) or mucosa-associated lymphatic tissue (MALT) lymphoma, splenic MZL (SMZL), and nodal MZL (NMZL). The clinical and molecular characteristics are different for each entity, with some shared phenotypic and genetic features. EMZL is the most common entity, accounting for approximately 70% of all MZLs. These neoplasms can arise at virtually any extranodal site and are commonly associated with chronic antigenic stimulation either as a result of infection (eg, Helicobacter pylori in the stomach) or autoimmune disease (eg, Sjögren syndrome and salivary glands). Several chromosomal translocations were also identified in EMZL, accounting in the aggregate for approximately one-third of all cases. SMZL accounts for approximately 20% of all MZLs. Patients typically present with an enlarged spleen and involvement of abdominal lymph nodes and BM. Approximately 40%-50% of SMZLs are associated with deletions of chromosome 7q. NMZL is the less common entity, representing approximately 10% of all MZLs. Patients with NMZL, by definition, have lymph node-based disease without involvement of the spleen or extranodal sites. The molecular pathogenesis of NMZL is still unknown.
authors.affiliation: Istituto di Ematologia Seràgnoli Università di Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000328:Adult; D000368:Aged; D015551:Autoimmunity; D002869:Chromosome Aberrations; D003582:Cytogenetics; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D011379:Prognosis; D013160:Splenic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D013997:Time Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome